These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 30012197)
41. Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes. Khan FH; Pandian V; Ramraj S; Natarajan M; Aravindan S; Herman TS; Aravindan N BMC Cancer; 2015 Jul; 15():514. PubMed ID: 26159519 [TBL] [Abstract][Full Text] [Related]
42. Computational methods for identification of recurrent copy number alteration patterns by array CGH. Shah SP Cytogenet Genome Res; 2008; 123(1-4):343-51. PubMed ID: 19287173 [TBL] [Abstract][Full Text] [Related]
43. Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. Depreeuw J; Stelloo E; Osse EM; Creutzberg CL; Nout RA; Moisse M; Garcia-Dios DA; Dewaele M; Willekens K; Marine JC; Matias-Guiu X; Amant F; Lambrechts D; Bosse T Clin Cancer Res; 2017 Dec; 23(23):7232-7241. PubMed ID: 28939739 [No Abstract] [Full Text] [Related]
44. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Silva GO; He X; Parker JS; Gatza ML; Carey LA; Hou JP; Moulder SL; Marcom PK; Ma J; Rosen JM; Perou CM Breast Cancer Res Treat; 2015 Jul; 152(2):347-56. PubMed ID: 26109346 [TBL] [Abstract][Full Text] [Related]
45. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data. Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114 [TBL] [Abstract][Full Text] [Related]
46. Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis. Li A; Chapuy B; Varelas X; Sebastiani P; Monti S Sci Rep; 2019 Nov; 9(1):16904. PubMed ID: 31729402 [TBL] [Abstract][Full Text] [Related]
47. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Mosse YP; Greshock J; Margolin A; Naylor T; Cole K; Khazi D; Hii G; Winter C; Shahzad S; Asziz MU; Biegel JA; Weber BL; Maris JM Genes Chromosomes Cancer; 2005 Aug; 43(4):390-403. PubMed ID: 15892104 [TBL] [Abstract][Full Text] [Related]
48. High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer. Wu Y; Schoenborn JR; Morrissey C; Xia J; Larson S; Brown LG; Qu X; Lange PH; Nelson PS; Vessella RL; Fang M J Mol Diagn; 2016 Jan; 18(1):131-43. PubMed ID: 26607774 [TBL] [Abstract][Full Text] [Related]
49. Predicting clinical outcomes in neuroblastoma with genomic data integration. Baali I; Acar DAE; Aderinwale TW; HafezQorani S; Kazan H Biol Direct; 2018 Sep; 13(1):20. PubMed ID: 30621745 [TBL] [Abstract][Full Text] [Related]
50. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification. Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595 [TBL] [Abstract][Full Text] [Related]
51. An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma. Formicola D; Petrosino G; Lasorsa VA; Pignataro P; Cimmino F; Vetrella S; Longo L; Tonini GP; Oberthuer A; Iolascon A; Fischer M; Capasso M J Transl Med; 2016 May; 14(1):142. PubMed ID: 27188717 [TBL] [Abstract][Full Text] [Related]
52. Genomic profiling reveals extensive heterogeneity in somatic DNA copy number aberrations of canine hemangiosarcoma. Thomas R; Borst L; Rotroff D; Motsinger-Reif A; Lindblad-Toh K; Modiano JF; Breen M Chromosome Res; 2014 Sep; 22(3):305-19. PubMed ID: 24599718 [TBL] [Abstract][Full Text] [Related]
53. Interaction-Based Feature Selection for Uncovering Cancer Driver Genes Through Copy Number-Driven Expression Level. Park H; Niida A; Imoto S; Miyano S J Comput Biol; 2017 Feb; 24(2):138-152. PubMed ID: 27759426 [TBL] [Abstract][Full Text] [Related]
54. Integration of molecular features with clinical information for predicting outcomes for neuroblastoma patients. Han Y; Ye X; Wang C; Liu Y; Zhang S; Feng W; Huang K; Zhang J Biol Direct; 2019 Aug; 14(1):16. PubMed ID: 31443736 [TBL] [Abstract][Full Text] [Related]
55. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma. Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123 [TBL] [Abstract][Full Text] [Related]
56. High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma. Yoshimoto T; Matsuura K; Karnan S; Tagawa H; Nakada C; Tanigawa M; Tsukamoto Y; Uchida T; Kashima K; Akizuki S; Takeuchi I; Sato F; Mimata H; Seto M; Moriyama M J Pathol; 2007 Dec; 213(4):392-401. PubMed ID: 17922474 [TBL] [Abstract][Full Text] [Related]
57. The Integrative Method Based on the Module-Network for Identifying Driver Genes in Cancer Subtypes. Lu X; Li X; Liu P; Qian X; Miao Q; Peng S Molecules; 2018 Jan; 23(2):. PubMed ID: 29364829 [TBL] [Abstract][Full Text] [Related]
58. Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients. Horlings HM; Lai C; Nuyten DS; Halfwerk H; Kristel P; van Beers E; Joosse SA; Klijn C; Nederlof PM; Reinders MJ; Wessels LF; van de Vijver MJ Clin Cancer Res; 2010 Jan; 16(2):651-63. PubMed ID: 20068109 [TBL] [Abstract][Full Text] [Related]
59. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression. Lasorsa VA; Formicola D; Pignataro P; Cimmino F; Calabrese FM; Mora J; Esposito MR; Pantile M; Zanon C; De Mariano M; Longo L; Hogarty MD; de Torres C; Tonini GP; Iolascon A; Capasso M Oncotarget; 2016 Apr; 7(16):21840-52. PubMed ID: 27009842 [TBL] [Abstract][Full Text] [Related]